Great Novel Therapeutics Biotech & Medicals (7427.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0007427007

Price
57.80 TWD
Market cap
3.06 bn TWD
P/E (2025)
–
P/S (2025)
2,538.16
Dividend yield
0.00 %
Net margin
-8,089.05 %
Return on equity (ROE)
-19.38 %
Return on assets (ROA)
-18.50 %

Great Novel Therapeutics Biotech & Medicals financials

Fiscal year20242025
Revenue1.69 m TWD1.21 m TWD
Gross profit1.02 m TWD-1.18 m TWD
Operating income-112.65 m TWD-99.54 m TWD
EBIT-104.80 m TWD-97.38 m TWD
Net income-104.92 m TWD-97.47 m TWD
Diluted EPS – continuing operations-2.55 TWD-2.18 TWD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.